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ABSTRACT
Introduction Combination vaccines containing whole- cell 
pertussis antigens were phased out from the Australian 
national immunisation programme between 1997 and 
1999 and replaced by the less reactogenic acellular 
pertussis (aP) antigens. In a large case–control study of 
Australian children born during the transition period, those 
with allergist diagnosed IgE- mediated food allergy were 
less likely to have received whole- cell vaccine in early 
infancy than matched population controls (OR: 0.77 (95% 
CI, 0.62 to 0.95)). We hypothesise that a single dose of 
whole- cell vaccine in early infancy is protective against 
IgE- mediated food allergy.
Methods and analysis This adaptive double- blind 
randomised controlled trial is investigating whether a 
mixed whole- cell/aP vaccine schedule prevents allergic 
disease in the first year of life. The primary outcome is 
IgE- mediated food allergy by 12 months of age. Secondary 
outcomes include new onset of atopic dermatitis by 6 or 
12 months of age; sensitisation to at least one allergen 
by 12 months of age; seroconversion in anti- pertussis 
toxin IgG titres after vaccination with aP booster at 18 
months of age; and solicited systemic and local adverse 
events following immunisation with pertussis- containing 
vaccines. Analyses will be performed using a Bayesian 
group sequential design.
Ethics and dissemination This study has been approved 
by the Child and Adolescent Health Service Human 
Research Ethics Committee, Perth, Western Australia 
(RGS 00019). The investigators will ensure that this 
trial is conducted in accordance with the principles of 
the Declaration of Helsinki and with the International 
Conference on Harmonisation Guidelines for Good Clinical 
Practice. Individual consent will be requested. Parents 
will be reimbursed reasonable travel and parking costs 
to attend the study visits. The dissemination of these 
research findings will follow the National Health and 
Medical Research Council of Australia Open Access Policy.
Trial registration number ACTRN12617000065392p.
INTRODUCTION
In comparison with those from other coun-
tries, Australian children have one of the 
highest prevalences of IgE- mediated food 
allergy in the first year of life1 and experience 
high rates of hospital- coded food- related 
anaphylaxis before 4 years of age.2
The development of oral tolerance to 
food allergens is likely to be food and dose- 
dependent, may have specific optimal 
windows of exposure and may be influenced 
by the integrity of the epithelial skin barrier.3 
The timing of introduction of peanuts for 
the primary and secondary prevention of 
IgE- mediated peanut allergy was examined 
in the Learning Early about Peanut Allergy 
(LEAP) trial.4 This showed that the introduc-
tion of peanuts between 4 and 11 months old 
decreased the risk of IgE- mediated peanut 
allergy by 80% at 5 years old in children with a 
history of severe atopic dermatitis, egg allergy 
or both, compared with children who avoided 
Strengths and limitations of this study
 ► The trial is powered to detect a meaningful reduc-
tion in food allergy by 12 months, a clinically import-
ant outcome.
 ► The trial uses a Bayesian group sequential design 
with prespecified stopping rules; compared with al-
ternative trial designs, this approach may be more 
efficient and more likely to yield a conclusive answer 
to the research question.
 ► This trial will not only provide safety and clinical 
efficacy data it may also offer mechanistic insights 
into the non- specific effects of vaccination on the 
developing immune system.
 ► As this trial is being conducted in a setting with 
very high coverage for maternal pertussis vaccina-
tion, we will not be able to examine the impact of 
maternally derived antibodies on infant immune re-
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all dietary peanut for 5 years.4 Meta- analysis suggests 
benefit from the early introduction of both, peanut and 
egg for the prevention of food allergy.5 This has informed 
infant feeding guidelines and since 2016 the Austral-
asian Society of Clinical Immunology and Allergy, among 
other expert groups, has supported their introduction in 
the first year of life.6 This advice has been extended to 
complementary feeding with dairy and wheat products,6 
although it remains uncertain whether this approach will 
decrease the prevalence of all IgE- mediated food allergy.
Pertussis-containing vaccines
The widespread use of whole- cell pertussis (wP)- containing 
vaccines through the WHO Extended Program of Immu-
nisation commenced in 1974.7 These wP formulations 
were initially provided as combination vaccines with 
diphtheria and tetanus toxoids but now wP- containing 
vaccines are mainly manufactured as multicomponent 
formulations that also include Haemophilus influenzae type 
b (Hib) and hepatitis B (HB) antigens (DTwP- Hib- HB).
wP formulations contain killed Bordetella pertussis organ-
isms. While they are inexpensive and still used in most 
countries, fever, irritability and other inflammatory 
manifestations (reactogenicity) driven by the cell wall 
components, as well as earlier (subsequently disproved) 
concerns about rare neurologic reactions, led to the 
development of aP vaccines in the late 1970s. aP- con-
taining vaccines first replaced wP- containing schedules in 
Japan from 1981,8 followed by other high- income coun-
tries from the mid- 1990s.9 Whereas aP formulations are 
better tolerated than wP,10 11 the reactogenicity of wP- only 
primary vaccine courses appears to be attenuated if 
given in an accelerated fashion and when the first dose 
is administered before the age of 3 months.12 Although 
no significant differences have been observed in the total 
number of serious adverse events (SAEs) within 60 days 
and within 6 months of either type of pertussis- containing 
vaccine,13 14 a lower risk of convulsions (RR: 0.47 (95% 
CI: 0.31 to 0.73)) and hypotonic hyporesponsive episodes 
(RR: 0.26 (95% CI: 0.08 to 0.81)) has been reported in aP 
compared with wP vaccinees.11
In Australia, the change- over to primary immunisation 
with aP- containing formulations occurred between 1997 
and 1999. Among Australian children who completed a 
three- dose primary course of pertussis vaccines during 
the period of transition, those primed with a first dose 
of wP (followed by doses of either aP or wP) appeared to 
have lower risk of pertussis in adolescence than those who 
were primed with aP- containing vaccines only.15
While aP vaccines induce a T helper 2 (Th2)- 
predominant phenotype, pathogen- associated molecular 
patterns within wP appear to elicit Th1/Th17 downstream 
polarisation.16 These differential immune phenotypes 
have been shown to persist into adulthood, despite 
repeated aP booster doses.17
Boosted IgE responses specific to coadministered 
tetanus and diphtheria toxoids have been reported 
in infants primed with aP doses only but not in infants 
primed with wP or mixed wP/aP schedules.18 19 IgE medi-
ated sensitisation to egg and milk antigens,19 20 as well 
as the induction of type 2 cytokines tobeta- lactoglobulin 
have also been described in aP- only primed infants. 
The clinical importance of these findings are yet to be 
determined.
Rationale for the trial
In the first year of life, there occurs a natural shift from 
an inherently skewed Th2 microenvironment in neonates, 
towards Th17 and then Th1 immune responses. This phase 
of the ontogeny of early life immunity coincides with the 
postnatal development of oral tolerance and represents 
a biologically plausible opportunity for targeting preven-
tion of IgE- mediated food allergy.
An initial ecological analysis of publicly available hospi-
talisation data suggested that in Australia, the phasing out 
of wP in favour of aP- only regimes for scheduled doses 
at 2, 4 and 6 months old coincided with an apparent 
rise in the incidence of admissions to hospital coded as 
food- associated anaphylaxis among young children. A 
case–control study subsequently found that children 
primed with a first dose of wP were less likely to be diag-
nosed with IgE- mediated food allergy than age- matched 
children primed with aP only (OR: 0.77 (95% CI, 0.62 to 
0.95)).21
We therefore hypothesise that priming with a first dose 
of wP helps to induce an allergy protective immunophe-
notype in susceptible individuals, while still being safe 
and well tolerated. The biological plausibility of this off- 
target effect is supported by the known pro- Th1/Th17 
immunomodulating properties of some cellular compo-
nents within wP formulations, which may help to balance 
the early life Th2- biased adaptive immune responses. This 
may in turn reduce the susceptibility to IgE- mediated 
food allergy in those individuals who are more prone to 
maintain a Th2- biased responses into later infancy.
Although the rationale for our study is supported by 
both immunological and clinical observational data from 
Australia,19 21 we note that a Swedish trial of children 
primed with DTwP versus DTaP in the early 1990s found 
no overall protection against IgE- mediated food allergy 
or food sensitisation.22 In that trial, food allergy was 
ascertained by parent- reported symptoms coupled with 
demonstration of IgE antibodies to the food of interest; 
skin prick testing only included milk and egg white anti-
gens at the age of 7 months, and only egg white at 2.5 
years of age; and no breakdown in skin prick positivity 
by food or type of food allergy was provided.22 Similarly, 
no association between the type of pertussis- containing 
vaccine and development of IgE- mediated food allergy 
was found in a birth cohort of the Isle of Wight.23 In post 
hoc analyses of trial data from a cohort of Australian 
children, recipients of a first dose of wP did not appear 
to have a lower risk of parent- reported asthma, atopic 
rhinitis or atopic dermatitis, at the ages of 5, 8 and 11.5 
years, compared with those who received a first dose of 
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one dose of wP had an apparent higher risk of peanut 
IgE- mediated sensitisation across the above- mentioned 
ages compared with recipients of aP- only doses.24 Neither 
study was adequately powered to exclude a clinically 
important difference in their chosen endpoints.
Here we describe the protocol of the Optimising Immu-
nisation Using Mixed Schedules (OPTIMUM) study, an 
adaptive clinical trial to investigate the effect of wP for the 
prevention of IgE- mediated food allergy.
METHODS AND ANALYSIS
Design
OPTIMUM is an investigator- initiated phase IV, two- stage, 
multisite, parallel, double- blind, adaptive, randomised 
controlled trial of a single dose of wP given at the age of 
6 to <12 weeks, followed by aP at 4 and 6 months, versus 
three aP doses only, for the prevention of IgE- mediated 
food allergy. The procedures for enrolment, intervention 
and the selection of primary and secondary endpoints are 
based on the principles of pragmatic Bayesian sequential 
trial design. The trial flowcharts (figures 1 and 2) and the 
timeline of the study visits (tables 1 and 2) are presented 
below.
Objectives
The primary objective is to determine whether, compared 
with the Australian standard of care of three priming 
doses of aP, a mixed wP/aP schedule (first dose of wP 
followed by doses of aP) protects against the development 
of IgE- mediated food allergy.
Study settings
OPTIMUM is being conducted at the Perth Children’s 
Hospital in Perth (PCH), Western Australia. Recruitment 
for stage 1 started in January 2018, with 150th participant 
randomised in January 2020. Stage 2 will also include sites 
in Sydney and Melbourne.
Patient and public involvement
Patients and consumers were involved in the design 
and conduct of this research. The proposed project was 
presented to a consumer reference committee prior 
to submission of the grant and following the award of 
funding. A consumer representative sits on the study 
steering committee.
Outcomes
The primary endpoint is IgE- mediated food allergy by the 
age of 12 months and confirmed, where necessary, before 
18 months. For the purpose of this trial, the study partic-
ipant will be considered to have reached the primary 
endpoint if there is evidence of sensitisation to a food on 
skin prick test, and either:
1. Unequivocal IgE- mediated food allergy, defined as 
(1) a positive oral food challenge or (2) clinician- 
diagnosed food anaphylaxis, with symptoms affecting 
at least 2 of the following: skin, gastrointestinal tract, 
respiratory tract, cardiovascular system, or
2. Highly probable IgE- mediated food allergy, defined 
as a history of food allergic reaction consistent with 
PRACTALL criteria.25
Secondary endpoints include (1) parent- reported 
clinician- diagnosed new onset of atopic dermatitis by 6 
Figure 1 Trial flowchart. Stage 1. DTaP, diptheria, tetanus, acellular pertussis; DTwP, diptheria, tetanus, whole- cell pertussis; 
Hib, Haemophilus influenzae type b; HepB, hepatitis B; IPV, inactivated poliovirus vaccine; NIP, National immunisation program; 
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or 12 months of age with a positive skin prick test to any 
allergen by 12 months of age (a weal measuring 1 mm 
greater than the negative control); (2) a fourfold or 
greater rise in pertussis toxin- specific IgG 21–35 days after 
a booster dose of aP at 18 months of age; (3) sensitisa-
tion to at least one allergen by 12 months of age, defined 
as a skin prick test with a weal measuring (a) 1 or (b) 
3 mm greater than the negative control; (4) solicited local 
and systemic adverse events following immunisation with 
pertussis- containing vaccines and (5) vaccination experi-
ence reported as either unsatisfactory or very unsatisfac-
tory on a 5- point Likert scale.
Additional stage 1- specific secondary endpoints are 
described in table 3.
Participants
In Perth, Western Australia, the identification of poten-
tially eligible study participants is carried out by trained 
staff during the antenatal and immediate postnatal 
periods in Saint John of God (SJOG) Subiaco and SJOG 
Mount Lawley hospitals, as well as through expressions 
of interest received via SJOG Murdoch Hospital and via 
email. Similar procedures will be implemented for the 
enrolment of study participants in Sydney and Melbourne.
Healthy infants aged 6 to <12 weeks old and born ≥32 
weeks’ gestation are eligible for enrolment. Additional 
eligibility criteria include: (1) parent with capacity to 
understand the information sheet, consent form and 
study- related procedures; (2) access to a telephone; (3) 
permission for other parties involved in the child’s treat-
ment and the Australian Immunisation Register (AIR) to 
be notified of their participation in this trial; (4) consent 
for the study staff to access the child’s immunisation 
history from AIR and/or local provider and (5) consent 
to obtain medical information from the child’s healthcare 
provider, pathology or medical records from enrolment 
until 1 month after the 18- month vaccines. Exclusion 
criteria are (1) history of pre- existing IgE- mediated 
food allergy and/or (2) pertussis infection; (3) receipt 
of any prior vaccine except for a single birth dose of HB 
vaccine within the first 7 days of life; (4) contraindica-
tion or allergy to any vaccine or vaccine components; (5) 
contraindication to paracetamol; (6) receipt or planned 
receipt of other investigational medicinal products until 
the final study visit; (7) receipt or planned receipt of 
any non- routine vaccines within 14 days after the first 
dose of pertussis- containing vaccine; (8) receipt of more 
than 2 weeks of immunosuppressants or immune modi-
fying drugs; (9) serious chronic illness including severe 
congenital anomalies affecting heart, brain and/or lungs; 
(10) history of any neurologic disorders or seizures; (11) 
administration of immunoglobulins and/or any blood 
products since birth or planned administration during 
the study period; (12) planned travel to any country that 
remains at risk of a poliomyelitis transmission at any time 
before 19 months of age.
Temporary exclusion criteria for vaccination visits 
include (1) fever; (2) acute moderate or severe illness 
without fever; and (3) for visits 2, 3 and 7 (stage 1 only) 
receipt of any vaccination within the preceding 14 days.
Study procedures
Baseline assessment
Participants are enrolled by a medical officer. On the 
day of the first study visit, written consent is obtained, 
and eligibility confirmed prior to randomisation. Demo-
graphics and other baseline data are recorded (table 4). 
A detailed history of all food exposure is also taken.
Figure 2 Trial flowchart. Stage 2. DTaP, diptheria, tetanus, acellular pertussis; DTwP, diptheria, tetanus, whole- cell pertussis; 
Hib, Haemophilus influenzae type b; HepB, hepatitis B; IPV, inactivated poliovirus vaccine; NIP, National immunisation program; 
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Because fever and irritability are common following 
immunisation with wP,10 11 a prophylactic dose of oral 
paracetamol (15 mg/kg) is administered immediately 
before or up to 30 min after vaccination, and the care-
giver advised to administer further doses 6 and 12 hours 
later.
Randomisation and blinding
Eligible participants are randomised 1:1 to receive a 
0.5 mL dose of the WHO- prequalified pentavalent formu-
lation of DTwP- HB- Hib (PENTABIO PT Bio Farma, 
study vaccine),26 or else a hexavalent formulation of 
DTaP- HB- Hib plus inactivated poliovirus vaccine (IPV) 
(INFANRIX HEXA, GlaxoSmithKline, comparator 
vaccine),27 as the first dose of the pertussis vaccination 
schedule between 6 and <12 weeks of age. This is given 
via intramuscular injection into the anterolateral aspect 
of the right thigh. Other scheduled 6- week doses are 
coadministered per Australia’s national immunisation 
programme.28
Randomisation is by computer- generated allocation 
sequence prepared by the trial statistician and based on 
randomly permuted blocks of size 6, 8 or 10. The rando-
misation codes are password- protected and held by the 
trial statistician. The allocation sequence is concealed 
from all blinded research staff in a non- transparent enve-
lope until completion of the study.
An unblinded pharmacist or research nurse obtains 
the next contiguous allocation and prepares the study 
or comparator vaccine into a clear 1 mL ready to 
administer syringe, labelled with the study participant’s 
number and their identifiers. The syringes are covered 
to prevent unblinding. At enrolment, vaccines may 
be administered by either a blinded or an unblinded 
nurse. If unblinded, this nurse has no further involve-
ment in the follow- up of the participant. Parents and 
all other research staff remain blinded until the study 
completion.
To maintain blinding while ensuring all participants 
receive at least three priming doses of IPV, a dose of 
DTaP- IPV (INFANRIX IPV, GlaxoSmithKline, catch- up 
vaccine),29 in lieu of DTaP, is administered to all partici-
pants at the age of 18 months.
The blinding process may be broken under compel-
ling medical or safety circumstances. Code breaks will 
be authorised by the coordinating principal investigator 
and will be communicated directly to the parents and/or 
medical team by the trial statistician.
Follow-up
Participants are reviewed in clinic by a research nurse. 
Where applicable, routine vaccinations are administered 
(figures 1 and 2 and tables 1 and 2). Questionnaires 
capture food exposure, supplementation with vitamins, 
probiotics, fish oils or others, clinical diagnoses of atopic 
dermatitis and IgE- mediated food allergy, pet ownership 
and childcare attendance. A memory aid is supplied for 
parents to record the onset of new medical events, mani-
festations of allergic diseases and exposure to foods for 
the duration of the study.
Laboratory testing
Venous bloods samples are obtained for the following 
analyses.





The change in the log titres of total IgE 
and tetanus toxoid, egg white and whole 
egg- specific IgE immediately prior the third 




Seropositive IgG titres against pertussis 
toxin, filamentous haemagglutinin and 
pertactin- specific IgG at 7 months of age
  A fourfold or greater rise in filamentous 
haemagglutinin and pertactin- specific IgG 
from 18 to 19 months of age
  Seroprotective IgG titres against all 
13- valent pneumococcal vaccine capsular 
polysaccharides, polyribosylribitol 
phosphate capsular polysaccharide of Hib 
and tetanus toxoid at 7 and 19 months of 
age
Hib, Haemophilus influenzae type b.
Table 4 Enrolment questionnaire




Gender, date of birth, place of residence, 
number and order of siblings, infant’s and 
parental ethnicity, parental country of birth and 
education, combined income, infant’s medical 
history and concomitant medications
Birth history Maternal gravidity and parity, intrapartum 
antibiotics, delivery type, Apgar score at 1 
and 5 min, gestational age at delivery, weight, 
length and head circumference at birth, 





on AIR or through 
vaccination 
providers
Pertussis- containing vaccine given in the 
preceding pregnancy and within the last 
5 years; seasonal influenza vaccination during 
the preceding pregnancy
Family history of 
atopic diseases
Parental- reported, clinician- confirmed history 
of asthma, atopic dermatitis, food allergy 




General appearance, skin assessment, 
objective SCORAD (SCORing Atopic 
Dermatitis, only for stage 2), temperature, 
weight, length, head circumference
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Plasma IgE studies
Total, tetanus toxoid and food allergen- specific IgE is 
measured in plasma at the age of 6, 7 and 19 months (stage 
1 only), using ImmunoCAP total and specific IgE assays 
(Thermo Fisher Scientific/Phadia, Uppsala, Sweden). 
These data will be used to calculate a fold change in the 
logarithm of IgE in each child from before their routine 
6- month vaccines to approximately 1- month postvaccina-
tion. IgE levels ≥0.35 kU/L are considered positive.
Vaccine antibody responses
Vaccine antigen- specific IgG titres are measured imme-
diately before and 21–35 days after the 6- month (stage 1 
only) and 18- month vaccine doses. These antibody levels 
are measured using a multiplex fluorescent bead assay.30
For stage 1, sera will be tested for IgG against B. pertussis 
antigens (pertussis toxin, filamentous haemagglutinin, 
pertactin, fimbriae agglutinogens 2–3), tetanus toxoid, 
capsular polysaccharide of Hib (Hib- PRP) and each of 
the 13- valent pneumococcal vaccine serotypes. For stage 
2, sera will only be tested for pertussis toxin- specific IgG 
in the first 300 study participants enrolled at PCH.
The putative protective thresholds for pertussis toxin 
and filamentous haemagglutinin- specific IgG are set at 
≥5 IU/mL, seroprotective IgG titres for tetanus toxoid 
at ≥0.1 IU/mL,31 Hib- PRP at ≥1.0 µg/mL32 and for all 
13- valent pneumococcal vaccine serotypes at ≥0.35 µg/
mL.33 34
We will measure the geometric mean titres of IgG anti-
bodies to pertussis toxin at 1 month after an 18- month aP 
booster dose.
Skin prick testing and oral food challenge
Participants are skin prick tested following the Austral-
asian Society of Clinical Immunology and Allergy 
guidelines.35
The allergen panel (Immunotek, Madrid, Spain) 
includes cow’s milk, hen’s egg, peanut, cashew, house 
dust mite (Dermatophagoides pteronyssinus), cat, rye grass 
(Lolium perenne), a positive control (10 mg/mL hista-
mine) and negative control (saline). Tests are performed 
using conventional single prick lancets (Entaco, distrib-
uted by Stallergenes) on the infant’s forearm or back, as 
indicated by the study site- specific standard operating 
procedure. At the discretion of the site principal inves-
tigator, skin prick testing can be performed before the 
age of 12 months to confirm IgE- mediated sensitisation 
in children suspected of having an IgE- mediated food 
reaction. In this case, the allergen panel will be decided 
by the site principal investigator and the test will be 
repeated as per study protocol at the 12 months’ study 
visit.
Food allergen skin prick tests >1 mm will be used to 
select infants for oral food challenge(s). The latter will be 
performed at the study site between 12 and 18 months of 
age, following modifications of the Australasian Society of 
Clinical Immunology and Allergy protocols, with interna-
tionally standardised scoring and stopping criteria.25
Additional studies
For both stages, parental consent is requested for a frac-
tion of the bloods to be used for future mechanistic 
studies. For stage 1, additional consent is requested 
for transcriptomic analysis and immunophenotyping 
of whole blood and cryopreserved mononuclear cells 
immediately before and 72 hours after the third dose of 
pertussis- containing vaccine to enable research into the 
effects of wP/aP priming on cellular immune functions.
Data collection
Case report forms and relevant source documentation 
are maintained for every trial participant enrolled in the 
study, either in paper or in electronic form. For stage 1, 
all case report forms are paper- based; for stage 2, case 
report forms and source documents may be paper or elec-
tronic based. Any paper records are stored under locked, 
confidential conditions. Data is entered onto a password- 
protected electronic database built in Medrio EDC for 
stage 1 and REDCap (Research Electronic Data Capture 
System) for stage 2. Automatic edit checks are created to 
ensure the data entered is consistent and correct. Study- 
related documentation will be archived until the youngest 
participant reaches 25 years old; or until 15 years after 
the end of the trial/publication (whichever is later); or as 
required by local guidelines.
Statistical analysis
The number and proportion of participants with IgE- 
mediated food allergy by 12–18 months of age will be 
summarised by treatment group, as well as the number 
of inconclusive results. The primary analysis will use inde-
pendent beta- binomial models with uniform priors for 
the primary endpoint in each study arm. The null hypoth-
esis that a first dose of DTwP- HB- Hib provides no reduc-
tion in IgE- mediated food allergy by 12 months of age 
compared with DTaP- HB- Hib will be rejected at the final 







where  θ1  is the probability of IgE- mediated food allergy 
by 12 months of age when given a first dose of DTwP- 
HB- Hib and  θ0  when given DTaP- HB- Hib, and D is the 
data at the final analysis. The parameter posteriors and 
their difference will be summarised by their means and 
highest density intervals.
Secondary analyses of the primary endpoint will assume 
a logistic regression model to investigate covariate adjust-
ment and post hoc investigation of subgroup effects. 
None of these subgroup analyses are prespecified and will 
be noted as post hoc when reporting.
Interim analyses
This trial allows interim analyses to be undertaken at 
prespecified sample sizes to decide whether the trial 
should be stopped early for futility or expected success. 
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stopping rules based on the data available at the time of 
the interim analysis. Due to the delay in observing the 
primary endpoint, the stopping rules will be based on 
predictive probabilities of detecting treatment effect 
rather than posterior probabilities of the effect itself.
Interim analyses will begin after 200 subjects have 
complete data on the primary endpoint. Subsequent 
interim analyses will occur every further 200 subjects 
with complete primary endpoint data until either a stop-
ping rule is met or enrolment is close to completion. If 
all subjects are enrolled up to the maximum sample size 
prior to a stopping rule being met, then no more interim 
analyses will be undertaken.
The predictive probability of success is calculated by 
imputing future data according to the model posterior 
predictive distribution given the data observed so far and 
calculating the expected trial outcome if future data were 
to be observed. That is,
 PPoSk = E[Pr(1 < 0|Dk, D̃k) > 0.95|Dk] 
is the predictive probability that the null hypothesis 
would be rejected at the posterior probability threshold 
0.95 if additional data,  
∼
Dk  were observed given the current 
data  Dk  . If the predictive probability of success at the 
currently enrolled sample size exceeds 0.95, then enrol-
ment will cease for expected success. If the predictive 
probability of success at the maximum planned sample 
size is less than 0.05 then enrolment will cease for futility. 
In either case, follow- up of participants already enrolled 
will continue to completion of their scheduled follow- up, 
and a final analysis will be undertaken as in the previous 
section.
These decision thresholds were selected on the basis of 
a thorough trial simulation study.
Sample size
A maximum sample size of 3000 participants (1500 per 
arm) is planned; 150 participants in stage 1 and up to 
2850 in stage 2. In accordance with trial simulations of 
the above design, we estimate the trial will have 85% 
power to detect a reduction in IgE- mediated food allergy 
by 12 months of age from 10% to 7% while controlling 
the probability of type I error at no more than 5%.
The sample size for this study is adaptive, therefore 
the actual trial sample size may be less than 3000 partic-
ipants. Based on simulation studies undertaken for the 
trial design, the actual sample size is likely to be at least 
1000 participants and very unlikely to be fewer than 500 
participants given the expected accrual rates and timing 
of the first interim analysis. We estimated a 69% proba-
bility of stopping early for futility if the null was true, and 
in the scenario above (reduction from 10% to 7% in the 
primary endpoint), we estimated 59% probability of stop-
ping early for expected success.
Safety reporting and trial oversight
Solicited and unsolicited adverse events following immu-
nisation are collected on diary cards in the 7 days after 
administration of pertussis- containing vaccines. Solicited 
local adverse events include injection site pain, erythema, 
induration and swelling; the solicited systemic adverse 
events recorded are fever ≥38°C (axillary), drowsiness, 
irritability, anorexia, vomiting, diarrhoea and restlessness. 
The definition and intensity grading for fever, diarrhoea 
and local reactions (except for immunisation site pain) 
follows the Brighton Collaboration guidelines.36–40 For 
other solicited adverse events, intensity grading scales 
based on impact on daily activities are used (grade 0 or 
absent; grade 1 if easily tolerated; grade 2, sufficiently 
discomforting to interfere with normal everyday activi-
ties and grade 3, if prevents normal everyday activities or 
requires significant medical intervention).
The following are considered adverse events of specific 
interest (AESI) and will be captured throughout the 
study: (1) vaccine failure including (but not limited to) 
laboratory confirmed or suspected: vaccine homotypic 
meningococcal disease, vaccine serotype invasive pneu-
mococcal disease, invasive Hib and pertussis and (2) 
hypotonic hyporesponsive episode as defined by the 
Brighton Collaboration Working Group.41 Any new illness 
that results in death, is life- threatening, requires inpatient 
hospitalisation or prolongation of existing hospitalisation 
and results in persistent or significant disability/incapacity 
is reported by the coordinating principal investigator to 
the sponsor as an SAE. SAEs deemed related to the study 
vaccines or procedures will be captured throughout the 
entire study period; if unrelated, they are only reported 
from visit 1 to 6 months postrandomisation. The relation-
ship of SAEs and AESIs to the trial vaccines is determined 
by a study physician.
An independent data safety and monitoring committee 
meets at least twice a year to monitor the overall conduct 
of the trial including adherence to stopping rules, safety- 
related endpoints and other outcome measures. Site- 
specific monitoring visits take place after the enrolment 
of the first 50 study participants. Subsequent visits are 
scheduled by the project manager or as per the coor-
dinating principal investigator and the data safety and 
monitoring committee request.
Ethics and dissemination
This study has been approved by the Child and Adoles-
cent Health Service Human Research Ethics Committee, 
Perth, Western Australia (RGS 00019). The trial is 
conducted in accordance with the principles of the Decla-
ration of Helsinki and with the International Conference 
on Harmonisation Guidelines for Good Clinical Practice. 
Individual consent is required for participation. Parents 
will be reimbursed reasonable travel and parking costs 
to attend the study visits. The dissemination of these 
research findings will follow the National Health and 
Medical Research Council Open Access Policy.
Final considerations
A successful trial is likely to reinforce the WHO position 
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regimes in countries with wP- based primary courses42; 
however, hurdles for the implementation of a mixed wP/
aP schedule are anticipated in other settings where regu-
latory barriers will need to be addressed and additional 
strategies to gain the confidence of consumers and stake-
holders will be needed.
EARLIER PROTOCOL VERSIONS
The present manuscript is based on version 11 of the study 
protocol. Following the award of Australian NHMRC 
funding for stage 2 of this project, a series of protocol 
amendments have been submitted and approved before 
any analyses and while all the investigators (including 
the trial statistician) remained blinded. The major 
amendment (protocol version 8, 106 study participants 
enrolled) and subsequent refinements (versions 9 to 11) 
are summarised as follows:
Inclusion/exclusion criteria: revised eligibility criteria 
allow for the enrolment of moderate to late preterm 
infants and infants with pre- existing atopic dermatitis 
(the latter have the highest risk of developing the primary 
outcome).3
Primary endpoint definition: the original primary 
endpoint was a composite outcome of either clinician- 
confirmed IgE- mediated food allergy or atopic derma-
titis by the age of 18 months. This has been modified as 
described in the outcome section of this manuscript.
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